- Companies
- Talis Biomedical
Talis Biomedical Valuation Multiples
Talis Biomedical is valued at $5M, a 12.6x revenue multiple. In the last fiscal year, Talis Biomedical revenue was $412K and Talis Biomedical EBITDA was ($61M).
Talis Biomedical Overview
About Talis Biomedical
Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.
Founded
2013
HQ
Employees
99
Website
Financials (Last FY)
EV
$5M
Valuation Multiples
Start free trialTalis Biomedical Financials
Talis Biomedical reported last fiscal year revenue of $412K and negative EBITDA of ($61M).
In the same fiscal year, Talis Biomedical generated $371K in gross profit, ($61M) in EBITDA losses, and had net loss of ($62M).
Talis Biomedical P&L
In the most recent fiscal year, Talis Biomedical reported revenue of $412K and EBITDA of ($61M).
Talis Biomedical is unprofitable as of last fiscal year, with gross margin of 90%, EBITDA margin of (14863%), and net margin of (15050%).
Financial data powered by Morningstar, Inc.
Talis Biomedical Stock Performance
Talis Biomedical has current market cap of $5M, and enterprise value of $5M.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5M | $5M | - | - | - | - | - |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTalis Biomedical Valuation Multiples
Talis Biomedical trades at 12.6x EV/Revenue multiple, and (0.1x) EV/EBITDA.
Talis Biomedical Financial Valuation Multiples
As of November 21, 2026, Talis Biomedical has market cap of $5M and EV of $5M.
Talis Biomedical has a P/E ratio of (0.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Talis Biomedical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Talis Biomedical Margins & Growth Rates
In the most recent fiscal year, Talis Biomedical reported gross margin of 90%, EBITDA margin of (14863%), and net margin of (15050%).
Talis Biomedical Margins
Data powered by FactSet, Inc. and Morningstar, Inc.
Talis Biomedical Operational KPIs
Talis Biomedical's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Talis Biomedical Competitors
Talis Biomedical competitors include Proteome Sciences, Zicix, IMD Companies, Euroinvestment, Co-Diagnostics, Amwill Healthcare, Constance Care, Speed Medical SAE, MedNation and Eukedos.
Most Talis Biomedical public comparables operate across Hospitals & Clinics and Laboratory Services.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $5M | ($2M) | 5.0x | - | (10.9x) | - | |||
| $731K | ($699K) | 10.8x | - | (11.3x) | - | |||
| - | - | - | - | - | - | |||
| - | ($1K) | - | - | (2294.1x) | - | |||
| $622K | ($48M) | 3.6x | 3.4x | (0.0x) | - | |||
| $5M | $1M | 1.3x | - | 4.7x | - | |||
| - | $9K | - | - | 548.3x | - | |||
| - | - | - | - | - | - | |||
This data is available for Pro users. Sign up to see all Talis Biomedical competitors and their valuation data. Start Free Trial | ||||||||
Talis Biomedical VC Funding History
Before going public, Talis Biomedical raised $31M in total equity funding, across 2 rounds.
Talis Biomedical Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Talis Biomedical
| When was Talis Biomedical founded? | Talis Biomedical was founded in 2013. |
| Where is Talis Biomedical headquartered? | Talis Biomedical is headquartered in United States. |
| How many employees does Talis Biomedical have? | As of today, Talis Biomedical has over 99 employees. |
| Is Talis Biomedical publicly listed? | Yes, Talis Biomedical is a public company listed on OTCM. |
| What is the stock symbol of Talis Biomedical? | Talis Biomedical trades under TLIS ticker. |
| When did Talis Biomedical go public? | Talis Biomedical went public in 2021. |
| Who are competitors of Talis Biomedical? | Talis Biomedical main competitors include Proteome Sciences, Zicix, IMD Companies, Euroinvestment, Co-Diagnostics, Amwill Healthcare, Constance Care, Speed Medical SAE, MedNation, Eukedos. |
| What is the current market cap of Talis Biomedical? | Talis Biomedical's current market cap is $5M. |
| What is the current revenue of Talis Biomedical? | Talis Biomedical's last fiscal year revenue is $412K. |
| What is the current EV/Revenue multiple of Talis Biomedical? | Current revenue multiple of Talis Biomedical is 12.6x. |
| Is Talis Biomedical profitable? | No, Talis Biomedical is not profitable. |
| How many companies Talis Biomedical has acquired to date? | Talis Biomedical hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Talis Biomedical has invested to date? | Talis Biomedical hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Talis Biomedical
Lists including Talis Biomedical
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




